Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2022 | The impact of SF3B1 mutation in myelofibrosis

Prithviraj Bose • 30 Sep 2022
SOHO 2022
Myelodysplastic Syndromes Myelofibrosis Myeloproliferative Neoplasms Luspatercept

Prithviraj Bose, MBBS, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the impact of SF3B1 mutation in myelofibrosis (MF) and other myeloid malignancies. Dr Bose first comments on the impact of this mutation on patients with myelodysplastic syndromes (MDS), and then explains how this mutation impacts patients with MF. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Prithviraj Bose

2:55
Current and emerging treatments for MF: an update from ASH 2023
Prithviraj Bose • 11 Dec 2023
2:21
An update from LIMBER-104: zilurgisertib +/- ruxolitinib in the management of MF-associated anemia
Prithviraj Bose • 11 Dec 2023
3:49
Bezuclastinib in adult patients with non-advanced systemic mastocytosis: initial results from Summit
Prithviraj Bose • 11 Dec 2023
3:30
LIMBER-104: zilurgisertib +/- ruxolitinib in patients with MF-associated anemia
Prithviraj Bose • 6 Sep 2023

Related Videos

2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
4:25
The challenges with accurately diagnosing and risk-stratifying patients with MDS
Klaus Metzeler • 16 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals